Discover
Stranded Technologies Podcast
Stranded Technologies Podcast
Author: Infinita
Subscribed: 11Played: 632Subscribe
Share
© Infinita City Inc.
Description
Infinita is building early clinical access pathways for biotech acceleration such as Prospera and Montana SB535. This is the Infinita community's main channel for news, podcast episodes, event announcements & more.
www.infinitatimes.com
www.infinitatimes.com
123 Episodes
Reverse
In this episode, Niklas sits down with attorneys Ian Huyett, who works on litigation and state-level health reform, and Andrew Ittleman, who represents FDA-regulated companies and litigated Regenerative Sciences v. FDA, to talk about where the FDA’s authority comes from and how it applies when a doctor treats a patient inside one state.The conversation goes on to cover the 1938 law behind that authority, the 2014 Regenerative Sciences case, what changed after the Supreme Court’s Loper Bright decision, and how states and medical boards could share some of that power.More about Ian Huyett’s work:* Ep. 103: Ian Huyett on Right to Try, Christian Techno Optimism, and Biotech Federalism* Corner Stone Action* Ian’s X* The Christian War on DeathMore about Andrew Ittleman’s work:* Andrew on LinkedIn* Andrew Ittelman’s law firm This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitatimes.com
Jessica Flanigan is a philosopher at the University of Richmond, where she holds the Richard L. Morrill Chair in Ethics and Democratic Values. She is the author of Pharmaceutical Freedom, which argues that patients should have the right to choose their own medicines, not just refuse them. Her work covers human challenge trials, seatbelt mandates, billionaires, and charismatic leadership, and she has won Richmond’s top awards for both teaching and scholarship.Today, she is also part of the Montana Experimental Treatment Review Board (ETRB), where she serves as the bioethics and patients’ rights member.More about Jessica Flanigan’s work:* Pharmaceutical Freedom* Jessica Flanigan personal website This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitatimes.com
Holly Fernandez Lynch is is Associate Professor of Medical Ethics and Law at the University of Pennsylvania, and one of the most influential voices in US bioethics on questions of clinical trial ethics, patient access, and research participant compensation. Holly was an opponent of the 2017 federal right-to-try act, joined Niklas to debate the problems with right-to-try vs. expanded access, and the potential merits and risks of Montana’s approach.Montana goes beyond federal right-to-try by dropping the life-threatening-disease requirement and lifting the ban on profit. Is a passed phase 1 trial enough protection against snake oil, how is paying a patient to access an unapproved treatment different from paying a research participant to accept risk, and can the data this generates might count as real evidence, or would it be just used as an excuse to skip the FDA process?More about Holly Fernandez Lynch’s work:* Holly on LinkedIn This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitatimes.com
John Cochrane, economist and professor of finance at Stanford Graduate School of Business and fellow at the Hoover Institution, joins the podcast to discuss the first principles of healthcare regulation. John debunks three arguments most commonly used to justify heavy healthcare regulation: that the poor need protection, that patients lack the information to choose well, and that people in a health crisis can’t shop around. Instead under a free market solutions such as private certification and insurance would price in the risk for consumers, bundle and unbundle better options up like in airlines, retail and other consumer industries.More about John Cochrane’s work:* After the ACA: Freeing the Market for Health Care* “Free Market Vaccines” on Cochrane’s blog* John on X This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitatimes.com
Niklas sits down with Dr. Anish Koka, a practicing cardiologist, and Dr. Anthony DiGiorgio, a neurosurgeon and academic, co-hosts of The Doctor’s Lounge. It’s a dense conversation about why the US healthcare system is structurally built to favor consolidation, bureaucracy, and large hospital systems, rather than independent doctors or patients.They break down specific rules working against independent practice, like Stark Law, which bars doctors from referring patients to equipment they own while hospitals face no such restriction, and Certificate of Need laws in over 35 states, which require government approval to open a new healthcare facility, often granted by boards run by existing competitors.The conversation traces how these incentives, not bad intentions, produced the consolidation defining American healthcare today, and looks at early state-level experiments, including Montana’s rollback of Certificate of Need, as a possible blueprint for reform.→ Listen to their podcast episode with Niklas on The Doctor’s LoungeMore about Anish Koka’s work:* Anish on X* Anish’s SubstackMore about Anthony DiGiorgio’s work:* Anthony on X* Anthony’s website This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitatimes.com








